人血白蛋白治疗终末期肝病研究进展

doi:10.3969/j.issn.1672-5069.2017.01.033

摘要/Abstract

摘要： 白蛋白是人体细胞外液中含量最多的蛋白,具有维持血浆胶体渗透压、抗炎、抗氧化、结合和转运物质以及调节凝血功能等多种生物学功能。终末期肝病患者体内白蛋白存在数量和功能的异常。应用人血白蛋白治疗终末期肝病,可以增加有效循环容量,减少肝肾综合征等并发症的发生;人血白蛋白还可用于分子吸附再循环系统,发挥吸附小分子物质、清除毒素等作用。本文简要回顾了白蛋白的生物学功能,综述了人血白蛋白在终末期肝病治疗中应用的相关临床研究新证据,同时分析了人血白蛋白在临床应用中存在的误区,以期为人血白蛋白在终末期肝病治疗中的应用提供指导。

关键词: 终末期肝病, 人血白蛋白, 肝肾综合征

Abstract: Human serum albumin is the most abundant extracellular protein,which plays an important biological roles such as maintaining plasma colloid osmotic pressure,having anti-inflammatory and antioxidant functions,binding and transporting materials,and regulating blood clotting. The quantity and quality of albumin are both abnormal in patients with end stage of liver diseases（ESLD）. Infusion of human serum albumin can increase the effective circulating volume,reduce the risk of complications such as hepatorenal syndrome in the treatment of patients with ESLD. Human serum albumin can also be used in molecular adsorbent recirculating system for the treatment of patients with hepatic failure,which might adsorpt small molecules and remove toxins. In this paper,we mainly reviewed the biological functions of albumin,the recent progress in its use in the treatment of patients with ESLD and some existing problems in clinical practice.

Key words: End stage of liver disease, Human serum albumin, Hepatorenal syndrome

李献平, 于伟燕综述, 赵彩彦审校. 人血白蛋白治疗终末期肝病研究进展[J]. 实用肝脏病杂志, 2017, 20(1): 115-119.

Li Xianping, Yu Weiyan, Zhao Caiyan.. What’s new in the application of human serum albumin in the treatment of patients with end stage liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 115-119.

参考文献

[1] Naudi A, Jove M, Cacabelos D, et al. Formation of S-（carboxymethyl）-cysteine in rat liver mitochondrial proteins: effects of caloric and methionine restriction. Amino Acids, 2013,44（2）:361-371.
[2] Yeggoni DP,Rachamallu A,Kallubai M,et al. Cytotoxicity and comparative binding mechanism of piperine with human serum albumin and alpha-1-acid glycoprotein. J Biomol Struct Dyn,2015,33（6）:1336-1351.
[3] Sand KM,Bern M,Nilsen J,et al. Unraveling the interaction between FcRn and albumin:Opportunities for design of albumin-based therapeutics. Front Immunol,2015,5:682.
[4] Di GD,Priora R,Coppo L,et al. The control of hyperhomocysteinemia through thiol exchange mechanisms by mesna. Amino Acids,2014,46（2）:429-439.
[5] Jalan R,Schnurr K,Mookerjee RP,et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology,2009,50（2）:555-564.
[6] Sakaida I,Kawazoe S,Kajimura K,et al. Tolvaptan for improvement of hepatic edema: A phase 3,multicenter,randomized,double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:73-82.
[7] Wong F. Drug insight:the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol,2007,4（1）:43-51.
[8] Rena NM,Wibawa ID. Albumin infusion in liver cirrhotic patients. Acta Med Indones,2010,42（3）:162-168.
[9] Fernandez J,Monteagudo J,Bargallo X,et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology,2005,42（3）:627-634.
[10] Salerno F,Navickis RJ,Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis:a meta-analysis of randomized trials. Clin Gastroenterol Hepatol,2013,11（2）:123-130.e1.
[11] Sen SM,Yachha SK,Bhatia V,et al. Safety,complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol,2015,63（5）:1126-1132.
[12] Appenrodt B,Wolf A,Grunhage F,et al. Prevention of paracentesis-induced circulatory dysfunction:midodrine vs albumin. A randomized pilot study. Liver Int,2008,28（7）:1019-1025.
[13] Hussain W,Khalid AB,Usmani T,et al. Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. Pak J Med Sci,2015,31（3）:592-596.
[14] Terra C,Guevara M,Torre A,et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis:value of MELD score. Gastroenterology,2005,129（6）:1944-1953.
[15] 张霞意,郭家伟,潘越. 白蛋白防治肝硬化并发肾功能损害的临床研究.实用肝脏病杂志,2010,13（3）：217-218.
[16] Barbano B,Sardo L,Gigante A,et al. Pathophysiology,diagnosis and clinical management of hepatorenal syndrome:from classic to new drugs. Curr Vasc Pharmacol,2014,12（1）:125-135.
[17] Ghosh S,Choudhary NS,Sharma AK,et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int,2013,33（8）:1187-1193.
[18] 孙亚冬,任祖海,叶启发. 特利加压素联合大剂量白蛋白治疗肝硬化肝肾综合征的疗效观察.实用肝脏病杂志,2007,10（2）：98-101.
[19] Salerno F,Gerbes A,Gines P,et al. Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis. Gut,2007,56（9）:1310-1318.
[20] Dundar HZ,Yilmazlar T. Management of hepatorenal syndrome. World J Nephrol,2015,4（2）:277-286.
[21] Cisneros-Garza LE,Munoz-Ramirez MR,Munoz-Espinoza LE,et al. The molecular adsorbent recirculating system as a liver support system:summary of Mexican experience.Ann Hepatol,2014,
13（2）:240-247.
[22] Lee JS. Albumin for end-stage liver disease. Korean J Intern Med,2012,27（1）:13-19.
[23] Olin P,Hausken J,Foss A,et al. Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation. Scand J Gastroenterol,2015,50（9）:1127-1134.
[24] Banares R,Nevens F,Larsen FS,et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.Hepatology,2013,57（3）:1153-1162.
[25] Marangoni R,Bellati G,Castelli A,et al. Development of high-efficiency molecular adsorbent recirculating system: preliminary report. Artif Organs,2014,38（10）:879-883.
[26] 郭利民,刘景院,徐道振,等. 分子吸附再循环系统治疗肝衰竭多脏器功能不全. 中华肝脏病杂志,2003,11（8）：455-457.
[27] Lavayssiere L,Kallab S,Cardeau-Desangles I,et al. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure.J Gastroenterol Hepatol,2013,28（6）:1019-1024.
[28] Sen S,Davies NA,Mookerjee RP,et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure:a randomized controlled study. Liver Transpl,2004,10（9）:1109-1119.
[29] Shen C,Zhao CY,Zhang R,et al. Obesity-related hepatocellular carcinoma:roles of risk factors altered in obesity. Front Biosci （Landmark Ed）,2012,17:2356-2370.
[30] 张庆辉,石好岭,侯森,等. 乙型病毒性肝炎肝硬化合并2型糖尿病患者发生原发性肝细胞肝癌的危险性分析.中华实用诊断与治疗杂志,2015,29（1）：76-77,80.
[31] 朱迎,刘学民,董健,等. 肝癌肝切除术后感染性并发症的危险因素分析. 中华肝胆外科杂志,2014,20（7）：495-498.
[32] 张风华,彭和平,王宝枝,等. 肝癌肝切除术后感染性并发症的危险因素分析. 中国普通外科杂志,2015,（1）：133-135.
[33] 赫嵘,蒋力,张珂,等肝癌合并肝硬化患者术后人血白蛋白应用方案的临床研究. 中华肝胆外科杂志,2014,20（1）：11-14.
[34] Pereira G,Guevara M,Fagundes C,et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol,2012,56（5）:1040-1046.
[35] Guevara M,Terra C,Nazar A,et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized,controlled study.J Hepatol,2012,57（4）:759-765.
[36] Rozga J,Piatek T,Malkowski P. Human albumin: old, new, and emerging applications.Ann Transplant,2013,18:205-217.